Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Next Previous
Trial Profile

Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PROREPAIR-B

    • Most Recent Events

    • 06 Jun 2023 Results of subgroup analysis (n= 729 from studies NCT03075735, NCT02922218, NCT02362620, and NCT02787837) assessing Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer patients receiving first line treatment stratified by BRCA status presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 21 Sep 2020 Results (n=95) of survival analysis from PROREPAIR-B patients who meet CARD study eligibility criteria presented at the 45th European Society for Medical Oncology Congress
    • 20 Jun 2020 Results (n=547) of a retrospective post-hoc analysis evaluating effects of the HSD3B1 genotype on the outcomes of previously androgen receptor pathway inhibition-naive subjects from two clinical trials: NCT02125357and NCT03075735 published in the Annals of Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top